{"id":892611,"date":"2025-10-06T09:43:27","date_gmt":"2025-10-06T13:43:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/"},"modified":"2025-10-06T09:43:27","modified_gmt":"2025-10-06T13:43:27","slug":"maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/","title":{"rendered":"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors"},"content":{"rendered":"

\nMaxCyte\u2019s Flow Electroporation\u00ae Technology will support efficient gene delivery to advance Moonlight Bio\u2019s engineered T cell therapies
\n<\/h2>\n
\n

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington.<\/p>\n

Moonlight Bio will deploy MaxCyte\u2019s Flow Electroporation\u00ae<\/sup> technology and ExPERT\u2122 platform to support the scalable development and manufacturing of its T cell therapy pipeline.<\/p>\n

\u201cWe\u2019re proud to partner with Moonlight Bio as they advance their gene-edited cell therapies through clinical development,\u201d said Maher Masoud, President and CEO of MaxCyte. \u201cOur globally supported, GMP-ready and regulatory-proven ExPERT\u2122 platform is built to accelerate clinical and commercial manufacturing and enable robust, scalable cell engineering. We\u2019re excited to support Moonlight Bio\u2019s innovative approach to optimizing gene-editing outcomes and advancing next-generation T cell therapies.\u201d<\/p>\n

\u201cWe look forward to collaborating with MaxCyte and leveraging their proven, GMP-compliant electroporation technology along with their deep scientific and regulatory expertise to build our clinical manufacturing process,\u201d said Jordan Jarjour, Chief Scientific Officer of Moonlight Bio. \u201cAt Moonlight Bio, we are committed to delivering T cell therapies that overcome the barriers to success in solid tumors, which account for the majority of the global cancer burden.\u201d<\/p>\n

Under the SPL, Moonlight Bio obtains non-exclusive research, clinical, and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae<\/sup> technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.<\/p>\n

\n About MaxCyte<\/strong>
\n
At MaxCyte\u00ae<\/sup>, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation\u00ae<\/sup> technology and SeQure\u2122 gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we\u2019ve been advancing cell engineering, shaping the future of medicine. Learn more at\u00a0maxcyte.com<\/u><\/a> and follow us on\u00a0X<\/u><\/a> and LinkedIn<\/u><\/a>.<\/p>\n

\n About Moonlight Bio<\/strong>
\n
Moonlight Bio, Inc. is a preclinical-stage biotechnology company based in Seattle, WA aiming to develop potency enhanced T cell therapies that provide new hope for patients suffering from cancer. Moonlight\u2019s core technologies were illuminated by nature itself and are designed to confront the disappointing reality that therapies for solid tumors are simply not potent enough to generate the deep and durable responses that patients urgently need. To learn more, connect with Moonlight Bio on LinkedIn<\/a> and visit us at moonlightbio.us<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Specifically, there is no assurance that MaxCyte will receive additional program-related revenue or other revenue under this SPL.<\/p>\n

Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 6, 2025. These documents are available through the Investor Menu, Financials section, under \u201cSEC Filings\u201d on the Investors page of our website at\u00a0http:\/\/investors.maxcyte.com<\/a>. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.<\/p>\n

\n MaxCyte Contacts:<\/strong>\n <\/p>\n

\n Investor Relations<\/strong>
\n
\n
\n Gilmartin Group<\/em>
\n <\/strong>
\n
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com\u00a0\u00a0<\/p>\n

\n Media Contact<\/strong>
\n
\n
\n Oak Street Communications<\/em>
\n <\/strong>
\n
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com<\/p>\n

\n Moonlight Bio Contacts:<\/strong>
\n
info@moonlightbio.us<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MaxCyte\u2019s Flow Electroporation\u00ae Technology will support efficient gene delivery to advance Moonlight Bio\u2019s engineered T cell therapies ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington. Moonlight Bio will deploy MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the scalable development and manufacturing of its T cell therapy pipeline. \u201cWe\u2019re proud to partner with Moonlight Bio as they advance their gene-edited cell therapies through clinical development,\u201d said Maher Masoud, President and CEO of MaxCyte. \u201cOur … <\/p>\n

Continue reading “MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892611","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MaxCyte\u2019s Flow Electroporation\u00ae Technology will support efficient gene delivery to advance Moonlight Bio\u2019s engineered T cell therapies ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington. Moonlight Bio will deploy MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the scalable development and manufacturing of its T cell therapy pipeline. \u201cWe\u2019re proud to partner with Moonlight Bio as they advance their gene-edited cell therapies through clinical development,\u201d said Maher Masoud, President and CEO of MaxCyte. \u201cOur … Continue reading "MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T13:43:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors\",\"datePublished\":\"2025-10-06T13:43:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/\"},\"wordCount\":800,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/\",\"name\":\"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=\",\"datePublished\":\"2025-10-06T13:43:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - Market Newsdesk","og_description":"MaxCyte\u2019s Flow Electroporation\u00ae Technology will support efficient gene delivery to advance Moonlight Bio\u2019s engineered T cell therapies ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington. Moonlight Bio will deploy MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the scalable development and manufacturing of its T cell therapy pipeline. \u201cWe\u2019re proud to partner with Moonlight Bio as they advance their gene-edited cell therapies through clinical development,\u201d said Maher Masoud, President and CEO of MaxCyte. \u201cOur … Continue reading \"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-06T13:43:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors","datePublished":"2025-10-06T13:43:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/"},"wordCount":800,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/","name":"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=","datePublished":"2025-10-06T13:43:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTkxNiM3MTc5MDA5IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapies-for-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892611"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}